South Africa has launched a R1.3 billion initiative to introduce Lenacapavir, a long-acting injectable drug for HIV prevention. Announced by President Cyril Ramaphosa, the program aims to reach nearly one million people by the end of 2027. This rollout, supported by the government, The Global Fund, and the Children’s Investment Fund Foundation, focuses on high-risk groups, including adolescent girls, young women, and pregnant mothers.
How does the new HIV prevention injection work?
Lenacapavir functions as a “capsid inhibitor,” a first-of-its-class medication that blocks the outer shell of the HIV virus. By preventing the virus from multiplying and invading human cells, the drug stops infection before it takes hold. According to clinical trials conducted in South Africa and Uganda, the treatment demonstrated near-100% effectiveness. Because the drug releases slowly into the body, patients only require an injection twice a year, which removes the daily burden of taking preventative pills and eliminates the risk of missed doses.
Where will the initial distribution take place?
The government is targeting 360 public health clinics across 24 high-burden districts for the first phase of the rollout. President Ramaphosa described the funding as a “catalytic investment,” noting that the partnership reflects the principle that lifesaving medicine should not be a privilege for a select few. This effort is aimed at managing the world’s largest HIV burden, with a specific focus on demographics at the highest risk of transmission.
Lenacapavir is designed to replace daily oral pills with just two injections per year. This biannual schedule is intended to drastically improve adherence rates compared to traditional preventative regimens.
What is the strategy for long-term affordability?
While the initial rollout relies on the brand-name version produced by U.S.-based Gilead, the high cost of the drug presents a significant economic hurdle. To address this, South Africa is utilizing a voluntary licensing agreement to facilitate the production of cheaper, generic versions of the injection. These generics are expected to reach the domestic market by 2027. This strategy aligns with a broader African continental goal to manufacture 60% of the region’s medical products locally by 2040.
Frequently Asked Questions
- How often is Lenacapavir administered?
The medication is an injectable drug that is given twice a year. - Who is the priority for this rollout?
The program focuses on high-risk populations, specifically adolescent girls, young women, and pregnant mothers. - When will generic versions be available?
Generic versions of the injection are expected to become available in the South African market by 2027. - Is the drug effective?
Clinical trials in South Africa and Uganda showed the drug has near-100% effectiveness in preventing HIV.
Are you interested in the future of public health policy in Africa? Join the conversation by leaving a comment below or subscribe to our newsletter for the latest updates on medical innovations.
